Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease

被引：0
|
作者：
White, William B. [1 ]
Gunawardhana, Lhanoo [2 ]
机构：
[1] Univ Connecticut, Sch Med, Cardiol, Farmington, CT USA
[2] Takeda Pharmaceut Int, Deerfield, IL USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2242
引用
收藏
页数：2
相关论文
共 50 条
  • [21] CARDIOVASCULAR EVENT ASSOCIATED WITH INITIATING ALLOPURINOL AND FEBUXOSTAT - ACUTE GOUT ATTACK AND CARDIOVASCULAR GOUT ATTACK
    Kim, H. J.
    Ahn, H. S.
    Kim, J.
    Ghang, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 106 - 106
  • [22] Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis
    Gao, Linggen
    Wang, Bin
    Pan, Ying
    Lu, Yan
    Cheng, Rui
    CLINICAL CARDIOLOGY, 2021, 44 (07) : 907 - 916
  • [23] Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol
    Pawar, Ajinkya
    Desai, Rishi J.
    Liu, Jun
    Kim, Erin
    Kim, Seoyoung C.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (07):
  • [24] `Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea
    Hoon Jeong
    Eunmi Choi
    Ahyoung Suh
    Myungsik Yoo
    Bonggi Kim
    Rheumatology International, 2023, 43 : 265 - 281
  • [25] Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
    Patoulias, Dimitrios Ioannis
    Doumas, Michael
    REUMATOLOGIA, 2021, 59 (06): : 423 - 424
  • [26] Liver Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease
    Lee, Jung Sun
    Hong, Seokchan
    Won, Jebum
    Kwon, Oh Chan
    Oh, Ji Sean
    Kim, Yong-Gil
    Lee, Chang Keun
    Yoo, Bin
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [27] 'Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea
    Jeong, Hoon
    Choi, Eunmi
    Suh, Ahyoung
    Yoo, Myungsik
    Kim, Bonggi
    RHEUMATOLOGY INTERNATIONAL, 2023, 43 (02) : 265 - 281
  • [28] Hepatic Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease
    Lee, Jung Sun
    Won, Jebum
    Kwon, Oh Chan
    Lee, Seung Soo
    Oh, Ji Seon
    Kim, Yong-Gil
    Lee, Chang-Keun
    Yoo, Bin
    Hong, Seokchan
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (05) : 527 - 531
  • [29] Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis
    Deng, Jian-Hao
    Zhang, Jia-Xing
    CLINICAL CARDIOLOGY, 2022, 45 (07) : 685 - 686
  • [30] Febuxostat equals allopurinol for gout prophylaxis
    不详
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2006, 73 (03) : 214 - 214
12345